Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

BACKGROUND: Gefitinib, an EGFR-tyrosine kinase inhibitor, significantly improve prognosis in patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the usefulness of MUC1 and vascular endothelial growth factor (VEGF) mRNA expression in peripheral blood as me...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Hu, Yi-Ming, Du, Yong-Jie, Zhu, Li-Rong, Qian, Hai, Wu, Yan, Shi, Wei-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246503/
https://www.ncbi.nlm.nih.gov/pubmed/25410981
http://dx.doi.org/10.1186/1471-2407-14-848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246503/
https://www.ncbi.nlm.nih.gov/pubmed/25410981
http://dx.doi.org/10.1186/1471-2407-14-848

Ejemplares similares